肿瘤细胞治疗研究
FRONTIER PAPERS
A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.
这些结果提示，CAR-NKG2A 技术可能克服 HVGR，尤其是在 NK 细胞上 NKG2A 表达升高的患者中。
CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.
嵌合抗原受体（CAR）工程化细胞疗法正从血液系统恶性肿瘤拓展至自身免疫性、炎症性和纤维化疾病，尽管各平台和适应证的证据成熟度差异显著。
In situ generation of NKG2D CAR T/NK cells via a tumor-targeted lipoplex for enhancing cancer immunotherapy.
Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.
嵌合抗原受体（CAR）-T 细胞疗法已改变了复发/难治性血液系统恶性肿瘤的治疗格局，在原本治疗耐药的患者中产生了高缓解率。
Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies.
基于嵌合抗原受体（CAR）的细胞疗法在治疗血液系统恶性肿瘤和实体瘤方面具有巨大前景。
Rewiring cellular immunotherapy: From CAR evolution to circuit innovations across diseases.
基于嵌合抗原受体 (CAR) 的免疫疗法已从早期的线性受体设计演变为日益精密的生物信号处理系统。
Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.
全球癌症负担日益加重，亟需创新的治疗策略。
Ultrasensitive In Vivo Imaging of Adoptive Immune Cell Distribution and Expansion Using Second Near-Infrared Conjugated Oligoelectrolyte Probes.
监测实体瘤中的过继性细胞治疗对于评估疗效和指导临床用药至关重要，但现有技术灵敏度差、背景信号高且会干扰治疗功能，使监测受到制约。
The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.
TME 是 RPT 与免疫治疗之间的关键桥梁；阐明这三者之间的相互作用对于推进联合策略至关重要。
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting.
嵌合抗原受体工程化自然杀伤（CAR-NK）细胞正成为血液系统恶性肿瘤的现货型免疫疗法，早期临床数据和良好的安全性特征为其提供了支持。
MEMBER ACCOUNT
登录成功会直接打开下一页。
